Tower Research Capital LLC TRC Grows Stock Position in Pfizer Inc. (NYSE:PFE)

Tower Research Capital LLC TRC lifted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 30.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 321,708 shares of the biopharmaceutical company's stock after purchasing an additional 75,034 shares during the quarter. Tower Research Capital LLC TRC's holdings in Pfizer were worth $8,535,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the 4th quarter valued at approximately $26,000. Rialto Wealth Management LLC acquired a new stake in Pfizer during the 4th quarter worth about $26,000. Kohmann Bosshard Financial Services LLC purchased a new stake in Pfizer during the 4th quarter valued at about $28,000. Noble Wealth Management PBC acquired a new position in shares of Pfizer in the fourth quarter valued at about $31,000. Finally, Bernard Wealth Management Corp. acquired a new stake in shares of Pfizer during the fourth quarter worth about $33,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of Pfizer stock traded down $0.07 during mid-day trading on Monday, reaching $22.07. 31,814,050 shares of the stock traded hands, compared to its average volume of 40,452,232. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The stock has a market capitalization of $125.17 billion, a PE ratio of 15.65, a PEG ratio of 0.64 and a beta of 0.67. The business has a 50-day moving average of $24.81 and a 200 day moving average of $26.11.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's revenue for the quarter was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.10 earnings per share. On average, analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Insider Activity at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the business's stock in a transaction on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.06% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently weighed in on PFE. UBS Group cut their price target on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating on the stock in a report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $31.07.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.